About
Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA
Averna Therapeutics is a biotechnology company specializing in the development of genomic medicines aimed at treating a wide array of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's proprietary technology focuses on inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome. These regions are selected to allow stable gene integration without disrupting normal cellular functions. By encoding their medicines in RNA, Averna utilizes validated, non-viral delivery platforms that are designed to be safe, efficient, scalable, and cost-effective. This approach also permits redosing with the intent to achieve curative outcomes.
Identity
| Name | Averna Therapeutics |
|---|---|
| Slug | averna-therapeutics |
| Type / kind | startup |
| Crunchbase ID | exsilio-therapeutics |
| Source _id | XLiMrj2b5u3GjfVI3DOVA5yhG0c9CObZfiNWwRagIvSnMZMZg1q383 |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country | Israel |
|---|---|
| HQ country code | IL |
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Ilan Ramon St, Ness Ziona, Israel |
Web & social
| Website | https://avernatx.com/ |
|---|---|
| https://www.linkedin.com/company/103303080 |
Classifications
Funding
| Total raised | $82.0M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}